FDA Clears First Blood Test for Alzheimer’s Disease: A new blood test simplifies Alzheimer’s detection, offering a reliable and less invasive alternative to PET scans and spinal taps.
FDA cleared Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio for marketing. The test measures two proteins in a blood sample to measure amyloid plaques associated with Alzheimer’s. The results are highly reliable but must be interpreted in conjunction with other patient clinical information.